ロード中...
A structure-based engineering approach to abrogate pre-existing antibody binding to biotherapeutics
Development of biotherapeutics is hampered by the inherent risk of immunogenicity, which requires extensive clinical assessment and possible re-engineering efforts for mitigation. The focus in the pre-clinical phase is to determine the likelihood of developing treatment-emergent anti-drug antibodies...
保存先:
| 出版年: | PLoS One |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Public Library of Science
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8301669/ https://ncbi.nlm.nih.gov/pubmed/34297759 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0254944 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|